Heart fix in one go: new study combines two procedures for AFib patients

NCT ID NCT06861673

Recruiting now Disease control Sponsor: Asklepios proresearch Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests doing two heart procedures at the same time for people with atrial fibrillation (AFib) who cannot take long-term blood thinners. The first procedure uses pulse field ablation to fix the heart's faulty electrical signals. The second closes off a small pouch in the heart (left atrial appendage) to lower stroke risk. Researchers will track 60 patients to see if the combined approach is safe and keeps the heart in normal rhythm after one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pulse field ablation (PFA) catheter and left atrial appendage closure (LAAC) device
What this could lead to: If successful, this combined approach could offer a one-time procedure to control atrial fibrillation and reduce stroke risk without long-term blood thinners.
What could go wrong: This is a small, retrospective registry study (60 people), not a randomized trial. Results may not apply broadly, and combined procedures carry risks like bleeding or heart sac inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION (AF)

Contacts and locations

Locations

Asklepios Klinik Altona
RECRUITING

Hamburg, Free and Hanseatic City of Hamburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.